Relationship of Body Composition, Metabolic Status, Antiretroviral Use, and HIV Disease Factors to Endothelial Dysfunction in HIV-Infected Subjects
Authors:
- 1 August 2010
- journal article
- research article
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 26 (8) , 847-854
Abstract
Vascular endothelial dysfunction may contribute to the increase in cardiovascular events during HIV-1 infection and its treatment. Antiretroviral therapy (ART), metabolic factors, lipodystrophy, and HIV infection itself may be involved. Ninety-six HIV-infected subjects were evaluated for endothelial function by measurement of brachial artery flow-mediated dilation (FMD) by ultrasound, single-slice CT of the abdomen and mid-thigh, whole-body dual x-ray absorptiomety (DXA) scans, and metabolic evaluations in a cross-sectional study. The median age was 40 years; 28% were female, 38% black, 3% Hispanic, and 59% white. Forty-nine (51%) were receiving ART, which included a PI in 28 (57%) and was non-PI based in 21 (43%). FMD (±SD) in subjects not on ART was 5.5 ± 4.3%, PI-ART 5.3 ± 3.6%, and non-PI-ART 5.5 ± 4.1% (p = 0.9). Age, race, CD4 cell count, and HIV RNA did not correlate significantly with FMD. Among ART-treated subjects in the lowest tertile of thigh subcutaneous fat area (range 3–31 cm2), FMD was 4.4 ± 3.5% and in the highest tertile (range 67–237 cm2) FMD was 6.8 ± 3.6% (p = 0.07, t-test). However, in multivariate analyses, no body composition measure showed a significant association with FMD for either the group as a whole or in ART-treated subjects. ART use, PI use, CD4 cell count, and HIV RNA levels were not associated with endothelial dysfunction by brachial FMD. A definitive association with measures of adiposity was not detected in multivariate analysis, suggesting that lipoatrophy may not be an important contributor to endothelial dysfunction in HIV-infected individuals on ART.Keywords
This publication has 35 references indexed in Scilit:
- Endothelial Activation Markers Are Linked to HIV Status and Are Independent of Antiretroviral Therapy and LipoatrophyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patientsAIDS, 2008
- No Impairment of Endothelial Function or Insulin Sensitivity with 4 Weeks of the HIV Protease Inhibitors Atazanavir or Lopinavir‐Ritonavir in Healthy Subjects without HIV Infection: A Placebo‐Controlled TrialClinical Infectious Diseases, 2008
- Endothelial Function in Human Immunodeficiency Virus-Infected Antiretroviral-Naive Subjects Before and After Starting Potent Antiretroviral TherapyJACC, 2008
- Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaborationThe Lancet, 2008
- Severe Impairment of Endothelial Function with the HIV-1 Protease Inhibitor Indinavir is not Mediated by Insulin Resistance in Healthy SubjectsCardiovascular Toxicology, 2008
- Proteinuria and Endothelial Dysfunction in Stable HIV-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Endothelial Function in HIV-Infected PersonsClinical Infectious Diseases, 2006
- HIV protease inhibitor ritonavir increases endothelial monolayer permeabilityBiochemical and Biophysical Research Communications, 2005
- Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapyAIDS, 2003